{"analyses":[{"ciLowerLimit":"0.473","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.158","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.189","paramType":"Hazard Ratio (HR)","paramValue":"0.740","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.94","upperLimit":"6.87","value":"5.32"},{"groupId":"OG001","lowerLimit":"3.29","upperLimit":"5.55","value":"4.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Objective response was achieved if they had a best overall response of CR or PR. Target lesions- CR: Disappearance of all lesions; any pathological lymph nodes have reduction in short axis to \\<10 mm. PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum. PD: At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study(the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions - CR: Disappearance of all lesions and normalization of tumour marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s). If a participant was not known to have died or have radiographically documented PD as of the data inclusion cutoff date, DOR was censored at the date of the last adequate tumor assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Placebo + Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with CR or PR. Participants censored in Ramucirumab + Docetaxel = 12 and in Placebo + Docetaxel = 5.","reportingStatus":"POSTED","timeFrame":"Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 28.4 Months)","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}